Replimune (REPL) Common Equity (2018 - 2026)

Replimune (REPL) has 9 years of Common Equity data on file, last reported at $166.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 60.04% year-over-year to $166.2 million; the trailing twelve-month figure through Mar 2026 stood at $166.2 million (down 60.04% YoY), and the FY2026 full-year result was $166.2 million, down 60.04% from the prior year.
• Common Equity retreated to $166.2 million in Q1 2026, from $210.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $595.3 million in Q4 2022 to a low of $166.2 million in Q1 2026.
• A 5-year average of $400.8 million and a median of $411.2 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 36.08% in 2022 and slumped 60.04% in 2026, its largest moves.
• Tracing REPL's Common Equity over 5 years: stood at $595.3 million in 2022, then retreated by 29.19% to $421.5 million in 2023, then gained by 14.43% to $482.4 million in 2024, then tumbled by 56.35% to $210.5 million in 2025, then decreased by 21.08% to $166.2 million in 2026.
• Business Quant data shows REPL's Common Equity at $166.2 million in Q1 2026, $210.5 million in Q4 2025, and $263.3 million in Q3 2025.